DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9

Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cocaine-Related Disorders; Substance-Related Disorders

Intervention: Flupenthixol (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: National Institute on Drug Abuse (NIDA)

Official(s) and/or principal investigator(s):
Herbert Kleber, M.D., Principal Investigator, Affiliation: New York State Psychiatric Institute

Summary

The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

Clinical Details

Official title: Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics

Study design: Primary Purpose: Treatment

Primary outcome:

Side effects

Drug use

Psychiatric symptoms

Cocaine craving

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Please contact site for information.

Locations and Contacts

New York State Psychiatric Institute, New York, New York 10032, United States
Additional Information

Starting date: March 1997
Last updated: August 16, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017